Dato-DXd, Osimertinib, Pemetrexed, Carboplatin — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-09-30 in 3mo
ESTIMATED |
READOUT
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osime
Phase 3 · Metastatic Non-small Cell Lung Cancer |
AZN ASTRAZENECA PLC | Dato-DXd, Osimertinib, Pemetrexed, Carbo |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|